Biologics plants, population genomics at scale and a regulator the World Health Organization rates at its highest maturity level. Three years into a twenty-year programme, the inward build is largely done.
The outbound record is the next chapter, and it is being written now.
The Global Health Exhibition will return on 25 to 28 October 2027 under the theme Invest in Health, its organiser announced, rescheduling the ninth edition that the Ministry of Health had set for 26 to 29 October 2026 at the Riyadh Exhibition and Convention Center (Malham). The organiser says the new dates allow more time to build international participation, partnerships and investment. A Global Health Exhibition Digital Forum runs from 26 October to 20 December 2026, with 30 industry webinars, 15 leadership interviews and a healthcare market report.
Why it matters. The exhibition is one of the Kingdom's main health-sector deal venues, reporting USD 35.5bn in deals at its 2025 edition, and the 2026 plan anticipated more than 130,000 healthcare professionals, 2,200 brands and 1,000 investors from over 100 countries. Fixed 2027 dates give exhibitors and investors a clear planning horizon.
Opportunity. Exhibitors, investors and international delegations gain a full year to build partnerships and deal pipelines for October 2027, with the Digital Forum keeping buyer and partner conversations running in the meantime.
Next milestone. The Global Health Exhibition Digital Forum opens on 26 October 2026
Dr Nerissa Naidoo, Associate Professor of Anatomy at Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), is studying whether the epigenetic changes that drive cartilage breakdown, inflammation and cellular stress can be modified to slow, stop or potentially reverse osteoarthritis. The work uses patient-derived cartilage cells from osteoarthritic knee and hip tissue to test pharmaceutical and nutraceutical interventions. It is funded by the Dubai Research, Development and Innovation Grant Initiative under the Dubai Future Foundation, with clinical collaboration from King's College Hospital London Dubai and teams at MBRU and Rashid Hospital.
Why it matters. The programme aims at disease-modifying therapy for a condition that affects more than 500 million people worldwide. It also shows Dubai's research grant scheme seeding translational precision medicine inside a local medical university.
A7i assessment
Opportunity. Patient-derived tissue models and epigenetic profiling give pharmaceutical and nutraceutical companies a Dubai platform for screening disease-modifying candidates in a Gulf patient population.
Next milestone. Validation of candidate interventions in advanced disease models, and biomarkers for earlier diagnosis
Pierre Fabre Laboratories has inaugurated a hub near Dubai Marina as the headquarters of its Middle East, Africa, Russia and Turkey subsidiary. The company operates directly in 44 countries and has been present in the region since the 1980s, with a medical portfolio in oncology, dermatology and rare diseases alongside dermo-cosmetic brands including Avène, Ducray and A-Derma. Chief executive Eric Ducournau linked the hub to the group's plan to lift revenue from €3.1bn in 2024 to at least €5bn by 2032.
Why it matters. A regional headquarters places commercial leadership for oncology, dermatology and rare-disease medicines in Dubai, confirming the emirate as the management base for multinational pharma across a wide emerging-market footprint.
A7i assessment
Opportunity. The company expects to manufacture closer to its markets in future, opening a conversation with UAE contract manufacturers and industrial free zones on regional production of medicines and dermo-cosmetics.
Next milestone. Senior appointments and partnership announcements from the new regional headquarters
KAUST says two biomedical microgravity experiments using brain cells, SSA-1 and SSA-2, are heading to the International Space Station on the SpaceX CR35 flight under the Saudi Space Agency's BioGravity Program, with Axiom Space and California's National Stem Cell Foundation as partners. Professor Imed Gallouzi leads the work, which targets Alzheimer's disease and multiple sclerosis, with Rayyanah Barnawi, the first Saudi woman astronaut and now a KAUST PhD candidate, and research scientist Dr Andrea Diaz Gaxiola, who prepared the precursor cells developed into brain cell types and organoids. The experiments set a baseline, and later missions are planned to use patient-derived samples to study disease progression and treatment responses.
Why it matters. The project connects the Kingdom's space and life-sciences programmes in a repeatable research pathway, with KAUST, the Saudi Space Agency and commercial spaceflight partners each playing a role.
A7i assessment
Opportunity. Space-based disease modelling opens a niche for organoid, assay and neuroscience partners to join follow-on Saudi missions that use patient-derived samples.
Next milestone. Follow-on missions using patient-derived samples to study disease progression and treatment response
SFDA Chief Executive Dr Hisham S. Aljadhey met chief executives and representatives of food companies at the authority's Riyadh headquarters on 13 October. He said the sector's performance indicators are improving across the Kingdom and that artificial intelligence is strengthening risk prediction, so preventive action can be taken before problems arise. Business leaders put forward proposals on upcoming priorities to inform the SFDA's next strategic framework.
Why it matters. The SFDA is drawing on industry input for its next strategy and putting AI-led risk prediction at the centre of food oversight, setting the direction for how food products will be regulated in the Kingdom.
A7i assessment
Opportunity. Food and nutrition producers, along with compliance and traceability technology providers, can position early around risk-based, AI-supported oversight as the framework takes shape.
Next milestone. Publication of the SFDA's next strategic framework
The Abu Dhabi Public Health Centre has introduced a nasal spray influenza vaccine for the first time for the 2026 to 2027 season, Gulf News reported on 12 October. It sits alongside standard injections for eligible people aged six months and above and a high-dose vaccine for those aged 65 and above, all free for eligible residents across Abu Dhabi, Al Ain and Al Dhafra. About 350,000 people were vaccinated in the emirate during the 2025 to 2026 season through 130 healthcare facilities and 11 outpatient pharmacies.
Why it matters. Offering three formats matched to age and health status moves the programme toward product-level choice. A needle-free option gives families a further route to vaccinating children, one of the season's priority groups.
A7i assessment
Opportunity. Vaccine makers with differentiated formats, such as intranasal or high-dose products, have a public programme that procures by product profile across hundreds of thousands of seasonal recipients.
Next milestone. Uptake figures for the 2026 to 2027 season, including doses delivered by nasal spray
The Abu Dhabi Public Health Centre (ADPHC) announced on 12 October a memorandum of understanding with Ultrahuman Healthcare to develop and validate a Biological Health Age model. The model combines clinical biomarker data with wearable health data to show how cardiovascular health, sleep, metabolism and recovery shape long-term health. The two-year agreement covers joint scientific research, clinical validation and responsible use of health data, with all data kept within the emirate under clinical oversight.
Why it matters. A validated biological age measure gives Abu Dhabi a population-scale endpoint for prevention, the unit in which longevity interventions will increasingly be judged. Keeping the data in the emirate under clinical governance positions the model as a public-health asset rather than a consumer metric.
A7i assessment
Opportunity. Diagnostics, wearables and preventive-health companies can align their biomarker panels with a publicly validated model, and longevity clinics gain a common outcome measure to report against.
Next milestone. Publication of the validation methodology and first results from the two-year programme
Gulf regulation targets industrially produced trans fats, with WHO validation for Saudi Arabia in
2024 and Oman in 2025, a UAE ban under its 2031 nutrition strategy and GSO caps across the GCC.
Official guidance in Saudi Arabia and the UAE recommends unsaturated vegetable oils such as olive,
canola and sunflower, alongside regular fish. The seed oil debate is active among Gulf consumers and in
global policy, where the January 2026 US Dietary Guidelines put olive oil first.
Momentum is expanding across investment, scientific research,
manufacturing and commercial biotechnology. Every figure links to the dataset behind it, and
emerging signals are tracked separately from these totals.
How A7i counts.
Emerging areas where science, capital, infrastructure and
regional demand are beginning to converge. Each is an A7i opportunity assessment built on the
verified records it cites.
Saudi Arabia, UAE
Biomanufacturing
Regional biologics capacity that serves the Gulf and takes contract work from outside it.
Why now
An SFDA-approved biologics plant is operating, a biosimilar pathway took effect in July 2026, and insulin localisation is contracted to cover more than half of Saudi need.
Regional advantage
Demand is concentrated, payers are public, and the same governments funding the plants also buy the output.
Capability required
Process development, qualified persons, and third-party contract volume to fill capacity between own products.
Next milestone
First biosimilar approved under the new guideline and manufactured in the Kingdom.
UAE, Qatar, Saudi Arabia
Genomics and precision medicine
Turning population sequencing into cohort selection, diagnostics and licensable research assets.
Why now
An Emirati cohort of 43,608 has been analysed and published, and that dataset has already been used to build a clinical trial cohort as well as to describe a population.
Regional advantage
Consanguinity rates make Gulf cohorts unusually informative for rare and monogenic disease, which is scientific value no larger population can substitute for.
Capability required
Bioinformatics depth, consent frameworks that permit commercial use, and retained rights over models trained on national data.
Next milestone
A second trial cohort selected from national genomic data, or a licensing agreement over it.
Saudi Arabia, UAE, Qatar
Cell and gene therapy
Delivery capability first, then a regional manufacturing site for advanced therapies.
Why now
A Saudi-developed CAR-T has SFDA clearance for Phase I, Qatar has delivered gene therapy to a patient, and Abu Dhabi has set out a gene-therapy manufacturing plan.
Regional advantage
Advanced therapies are made close to the patient by necessity, which suits a region willing to fund the infrastructure.
Capability required
Vector manufacturing, apheresis and cell-handling capacity, and a reimbursement route for one-time high-cost therapies.
Next milestone
First patient dosed in the Saudi CAR-T trial, and a confirmed site for Abu Dhabi manufacturing.
Saudi Arabia, UAE
AI-enabled drug discovery
Discovery platforms built on regional data rather than licensed from outside it.
Why now
Three AI discovery companies are in the Saudi accelerator cohort, and Abu Dhabi has signed AI screening against its biobank.
Regional advantage
National biobanks and genome programmes give regional platforms proprietary training data unique to the Gulf.
Capability required
Published validation, compute at scale, and data-rights terms that let a platform keep what it trains.
Next milestone
Published clinical validation of a model trained on Gulf data.
UAE, Saudi Arabia
Advanced diagnostics
Accredited laboratory capability the region owns, and can export as a service.
Why now
PureHealth now operates London hub laboratories serving more than 50 hospitals, and the SFDA runs a reference laboratory in Dammam.
Regional advantage
Owning accredited Western laboratories gives methods and accreditation that can be brought home rather than rebuilt.
Capability required
Assay development of its own, building on the platforms it already operates.
Next milestone
Laboratory methods, accreditation or staff rotating from the United Kingdom into Gulf facilities.
Saudi Arabia
Vaccines
Domestic dose capacity, the health capability that matters most in a crisis.
Why now
Lifera signed vaccine localisation memoranda with Pfizer, Sanofi and MSD on a single day, each covering knowledge and technology transfer.
Regional advantage
A single public buyer can guarantee offtake, which is what makes vaccine capacity financeable.
Capability required
Fill and finish at scale, cold chain, and eventually drug substance as well as formulation.
Next milestone
One of the three memoranda converting to a definitive agreement, and a first localised batch.
Abu Dhabi licensed the world's first longevity medicine centres
and Dubai created a longevity regulator by law. A7i tracks aesthetics, wellness and preventive
health as part of the biotechnology economy, because in the Gulf that is what they have become.
Sovereign balance sheets, announced partnership values and venture rounds are three different instruments. Told apart, they show a market building faster in manufacturing than in equity.
Companies and platforms across six markets, a 62-strong Saudi accelerator cohort and a university spinout already selling abroad. Intellectual property is the next frontier.
Eleven translation programmes now run across the region, from a home-grown CAR-T to gene therapy delivered in Doha. The next move is owning more of what gets tested.
An operating biologics facility, insulin lines building toward 2027 and vaccine agreements with three of the largest manufacturers in the world. The build is under way, and commissioning and output are the next milestones to track.
A7i Intelligence is an independent Gulf biotechnology intelligence publication. It tracks
the companies, capital, science, infrastructure, regulation, intellectual property and
emerging technologies building the Gulf biotechnology economy.
Every figure is traceable to a named source with a publication date and a
verification date.
The Wire, by email
Biotechnology, diagnostics, capital, regulation, science and manufacturing across the six
Gulf markets. Every item is selected for its significance and carries a direct source and a
verification date.
